Tejara Capital’s Cardiol Therapeutics CRDL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$12.3M Buy
7,420,429
+2,306,607
+45% +$3.67M 6.02% 5
2026
Q2
$5.42M Sell
5,113,822
-16,300
-0.3% -$20.6K 2.23% 15
2026
Q1
$6.93M Hold
5,130,122
– – 2.28% 12
2025
Q4
$4.89M Buy
5,130,122
+2,500,000
+95% +$2.62M 1.15% 18
2025
Q3
$2.81M Sell
2,630,122
-635,697
-19% -$771K 1.47% 25
2025
Q2
$4.44M Buy
3,265,819
+70,829
+2% +$82.5K 2.06% 14
2025
Q1
$3.1M Buy
3,194,990
+79,553
+3% +$97.7K 1.2% 24
2024
Q4
$3.99M Buy
3,115,437
+1,344,167
+76% +$2.27M 2.61% 14
2024
Q3
$3.51M Buy
1,771,270
+49,027
+3% +$102K 1.67% 21
2024
Q2
$3.48M Buy
1,722,243
+77,833
+5% +$165K 1.26% 29
2024
Q1
$2.98M Buy
1,644,410
+527,734
+47% +$711K 1.09% 29
2023
Q4
$942K Buy
1,116,676
+471,219
+73% +$400K 0.39% 47
2023
Q3
$578K Buy
645,457
+148,396
+30% +$142K 0.33% 51
2023
Q2
$442K Buy
497,061
+56,435
+13% +$37.3K 0.22% 59
2023
Q1
$215K Hold
440,626
– – 0.11% 76
2022
Q4
$225K Buy
+440,626
New +$269K 0.13% 85

Other funds holding CRDL

Tejara Capital's CRDL Position: Q3 2026 in Review

Tejara Capital increased its Cardiol Therapeutics (CRDL) stake by 45% in Q3 2026, buying an estimated $3.67M and bringing the position to 7,420,429 shares worth $12.3M. The position accounts for 6.02% of the portfolio, ranked #5.

Tejara Capital first reported a position in CRDL in Q4 2022 and has held it in 16 quarters since. 44 funds tracked by Wall St. Rank hold CRDL as of Q3 2026.

  • Tejara Capital held 7,420,429 shares of Cardiol Therapeutics worth $12.3M as of Q3 2026.
  • Tejara Capital bought 2,306,607 Cardiol Therapeutics shares in Q3 2026, an estimated $3.67M.
  • Cardiol Therapeutics made up 6.02% of Tejara Capital's portfolio in Q3 2026, its #5 holding.
  • Tejara Capital first reported a position in Cardiol Therapeutics in Q4 2022 and has held it in 16 quarters since.
  • 44 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q3 2026.

Based on Tejara Capital's 13F filing for Q3 2026, filed 9 Nov 2026.